Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab Post-Allo HSCT in AML/MDS
NCT02846376Phase 1Terminated
- Sponsor
- Hackensack Meridian Health
- Start
- Mar 2019
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab and ipilimumab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by Hackensack Meridian Health. Primary endpoint: Treatment-related limiting toxicity. Started Mar 2019; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02846376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02846376.